<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Use of osteoclast inhibitors in early breast cancer</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Use of osteoclast inhibitors in early breast cancer</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Use of osteoclast inhibitors in early breast cancer</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Catherine Van Poznak, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Daniel F Hayes, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Sadhna R Vora, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Oct 26, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Breast cancer is the most common female cancer worldwide. The prognosis of fully treated early breast cancer is usually very good, in part due to systemic therapies reducing the risk of recurrence. For example, in the United States, estimates are that approximately 90 percent of patients will survive five years or more following their initial diagnosis [<a href="#rid1">1</a>]. Therefore, the long-term toxicities of breast cancer therapies need to be considered. (See  <a class="medical medical_review" href="/z/d/html/788.html" rel="external">"Selection and administration of adjuvant chemotherapy for HER2-negative breast cancer"</a> and  <a class="medical medical_review" href="/z/d/html/773.html" rel="external">"Adjuvant systemic therapy for HER2-positive breast cancer"</a> and  <a class="medical medical_review" href="/z/d/html/749.html" rel="external">"Adjuvant endocrine and targeted therapy for postmenopausal women with hormone receptor-positive breast cancer"</a> and  <a class="medical medical_review" href="/z/d/html/120706.html" rel="external">"Adjuvant endocrine therapy for premenopausal women with hormone receptor-positive breast cancer"</a>.)</p><p>Systemic therapies used to treat early breast cancer can be associated with loss of bone mineral density (BMD) and increased risk of osteoporotic fractures [<a href="#rid2">2</a>]. Recent international guidelines outline managing bone in the setting of breast cancer [<a href="#rid3">3,4</a>]. Bisphosphonates and <a class="drug drug_general" data-topicid="15575" href="/z/d/drug information/15575.html" rel="external">denosumab</a> are potent inhibitors of osteoclast activity. They are US Food and Drug Administration approved for managing osteoporosis and bone metastases from a variety of malignancies. They aid in treating therapy-related bone loss and complement nutritional (calcium and vitamin D), exercise, and healthy lifestyle behaviors. They have also been evaluated as adjuvant treatments in breast cancer.</p><p>This topic will review the use of bisphosphonates and <a class="drug drug_general" data-topicid="15575" href="/z/d/drug information/15575.html" rel="external">denosumab</a> for bone health and their impact on breast cancer outcomes in the adjuvant setting.</p><p>Methods to assess risk of fracture (eg, using history, physical exam, algorithms such as the fracture risk assessment tool [FRAX]), imaging BMD, and optimal intake of calcium and vitamin D are discussed elsewhere.</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/2061.html" rel="external">"Osteoporotic fracture risk assessment"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/2046.html" rel="external">"Screening for osteoporosis in postmenopausal women and men"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/2023.html" rel="external">"Calcium and vitamin D supplementation in osteoporosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/2060.html" rel="external">"Evaluation and treatment of premenopausal osteoporosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/2064.html" rel="external">"Overview of the management of low bone mass and osteoporosis in postmenopausal women"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/2060.html" rel="external">"Evaluation and treatment of premenopausal osteoporosis"</a>.)</p><p></p><p class="bulletIndent1">Additionally, the utility of osteoclast inhibitors in the management of bone metastases from breast and other cancers is reviewed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/2801.html" rel="external">"Osteoclast inhibitors for patients with bone metastases from breast, prostate, and other solid tumors"</a>.)</p><p></p><p>In this topic, we will use the terms "woman/en" or "patient" to describe genetic females. However, we recognize that not all people with breasts identify as female, and we encourage the reader to consider transgender and gender nonbinary individuals as part of this larger group.</p><p>The American Society of Clinical Oncology guideline on the management of male breast cancer addresses bone-modifying agents for this population [<a href="#rid5">5</a>].</p><p class="headingAnchor" id="H2"><span class="h1">TREATMENT FOR BREAST CANCER THERAPY-ASSOCIATED BONE LOSS</span><span class="headingEndMark"> — </span>This section is specific to osteoporosis prevention and treatment. Osteoclast inhibitor therapy as adjuvant anticancer therapy is discussed in a separate section. (See <a class="local">'Choice of bisphosphonate for anticancer therapy'</a> below.)</p><p class="headingAnchor" id="H1084336918"><span class="h2">Risk factors</span><span class="headingEndMark"> — </span>Women with a history of breast cancer may be at increased risk of osteoporosis and fracture secondary to anticancer therapies administered [<a href="#rid3">3,4</a>]. Osteoporosis is associated with an increased risk of fracture and can be associated with significant morbidity, mortality, disfigurement, and loss of self-esteem, as well as health care expenditure [<a href="#rid6">6</a>].</p><p>Estrogen is an important hormone for bone homeostasis in women and it is an important target for hormone receptor-positive breast cancer, for which antiestrogen therapies are used. Therefore, anticancer therapies that decrease circulating estrogen levels or estrogen signaling may be associated with a negative impact on bone by decreasing bone mineral density (BMD) and increasing risk of osteoporotic fractures.</p><p>Adjuvant systemic therapies for breast cancer that are associated with an increased risk for bone loss include [<a href="#rid3">3,4</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Antiestrogen treatments (chemical or surgical ovarian ablation, aromatase inhibition (AI), and in premenopausal patients, <a class="drug drug_general" data-topicid="9972" href="/z/d/drug information/9972.html" rel="external">tamoxifen</a>)</p><p class="bulletIndent1"><span class="glyph">●</span>Chemotherapies that promote premature ovarian dysfunction</p><p class="bulletIndent1"><span class="glyph">●</span>Supportive medications, such as glucocorticoids</p><p></p><p>By contrast, the use of <a class="drug drug_general" data-topicid="9972" href="/z/d/drug information/9972.html" rel="external">tamoxifen</a> provides protection against bone density loss in postmenopausal women. However, tamoxifen is associated with accelerated loss of bone mass in premenopausal women [<a href="#rid7">7</a>]. (See  <a class="medical medical_review" href="/z/d/html/2068.html" rel="external">"Selective estrogen receptor modulators for prevention and treatment of osteoporosis", section on 'Tamoxifen'</a>.)</p><p class="headingAnchor" id="H603689126"><span class="h2">General measures</span><span class="headingEndMark"> — </span>The foundation of bone health involves optimizing calcium and vitamin D intake, use of weight-bearing exercises, and limiting or removing bone-offending medications and behaviors, such as tobacco use [<a href="#rid4">4</a>]. (See  <a class="medical medical_review" href="/z/d/html/2064.html" rel="external">"Overview of the management of low bone mass and osteoporosis in postmenopausal women", section on 'Lifestyle measures to reduce bone loss'</a>.)</p><p class="headingAnchor" id="H3999198707"><span class="h2">Screening and indications for pharmacologic therapy</span><span class="headingEndMark"> — </span>Screening for bone loss among women with a history of breast cancer includes a detailed history, physical exam, and medication review. Some women should also be screened with dual-energy x-ray absorptiometry (DXA) or another tool that reliably assesses the risk of fragility fracture. (See  <a class="medical medical_review" href="/z/d/html/15781.html" rel="external">"Approach to the patient following treatment for breast cancer", section on 'Evaluation of bone density'</a>.)</p><p>Indications for pharmacologic therapy for bone health are the same for women with a history of breast cancer as for the general population and are discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/2064.html" rel="external">"Overview of the management of low bone mass and osteoporosis in postmenopausal women", section on 'Patient selection'</a>.)</p><p class="headingAnchor" id="H4"><span class="h2">Premenopausal women</span><span class="headingEndMark"> — </span>Although less than one-third of newly diagnosed breast cancer cases occur in premenopausal women, the risk of long-term bone-related toxicity as a consequence of cancer-related therapy is of unique concern, primarily because of patients' anticipated long life expectancy [<a href="#rid1">1</a>]. Breast cancer therapy-induced bone loss in premenopausal women may occur due to ovarian dysfunction secondary to chemotherapy, or endocrine treatment (gonadotropin-releasing hormone agonists) or oophorectomy, as well as due to oral antiestrogen therapies. The risk of chemotherapy-induced ovarian dysfunction and associated bone loss is impacted by the patient's age at time of therapy and the chemotherapy regimen used. Note that the risk of accelerated bone loss with ovarian dysfunction may not be permanent; some women with chemotherapy-induced amenorrhea will experience resumption of menses during follow-up, which may allow BMD to improve, although it may not return to baseline [<a href="#rid8">8</a>]. (See  <a class="medical medical_review" href="/z/d/html/745.html" rel="external">"Overview of side effects of chemotherapy for early-stage breast cancer", section on 'Chemotherapy-induced amenorrhea'</a>.)</p><p>Among premenopausal women treated with chemotherapy, the rate of BMD loss may approach 3 to 8 percent at the lumbar spine within 12 months of initiating chemotherapy [<a href="#rid9">9-12</a>]. BMD loss may occur in premenopausal women as a result of adjuvant <a class="drug drug_general" data-topicid="9972" href="/z/d/drug information/9972.html" rel="external">tamoxifen</a> [<a href="#rid8">8,13,14</a>], or use of ovarian suppression (chemical or surgical) [<a href="#rid13">13,15</a>]. Retrospective data suggest that at five years both adjuvant chemotherapy and biochemically induced menopause with GnRH therapy have a similar impact on loss of BMD [<a href="#rid16">16</a>]. However, the cumulative loss of BMD due to cancer therapy-induced menopause, which occurs acutely, versus BMD loss in natural menopause, which proceeds over years, has not been formally studied. In addition, the fracture risk attributable to these changes in BMD has not been quantified. Finally, it is unclear whether entering menopause by any particular mode ultimately has a greater lifetime impact on fracture.</p><p>The evaluation and treatment of women at risk for premenopausal osteoporosis is discussed in more detail separately. (See  <a class="medical medical_review" href="/z/d/html/2060.html" rel="external">"Evaluation and treatment of premenopausal osteoporosis"</a> and  <a class="medical medical_review" href="/z/d/html/2061.html" rel="external">"Osteoporotic fracture risk assessment", section on 'Clinical risk factor assessment'</a>.)</p><p class="headingAnchor" id="H1282083768"><span class="h3">Bisphosphonates</span><span class="headingEndMark"> — </span>When a pharmacologic intervention is indicated to reduce the risk of osteoporosis or fracture (eg, T score of -2.5 or lower on a DXA scan or a history of fracture due to low BMD), then a bisphosphonate is the drug class of choice in premenopausal women with a history of breast cancer [<a href="#rid17">17-19</a>].</p><p>Bisphosphonate therapy in premenopausal women with chemotherapy-induced ovarian failure and/or ovarian suppression may preserve or improve BMD, but whether it decreases fractures is not clearly defined [<a href="#rid17">17-19</a>].</p><p>It is of note that bisphosphonates may leach from bone over time and can cross the placenta. Hence, the bisphosphonates are classified as at risk for fetal harm, and women of childbearing potential should be advised of this risk, which may persist after discontinuation. The bisphosphonates that are US Food and Drug Administration (FDA)-approved for osteoporosis prevention or treatment do not have an indication specific to premenopausal women. If bisphosphonate use is indicated and the woman is of childbearing potential, consideration should be given to using a multidisciplinary approach to decision-making (obstetrics, endocrinology, oncology). For women of childbearing potential who may hold anti-estrogen therapy in order to pursue pregnancy, the impact on bone mineral density and fracture risk has not been studied. Further discussion of breast cancer and pregnancy, and of use of antiresorptive agents during pregnancy, is found elsewhere. (See  <a class="medical medical_review" href="/z/d/html/15801.html" rel="external">"Gestational breast cancer: Treatment"</a> and  <a class="medical medical_review" href="/z/d/html/2060.html" rel="external">"Evaluation and treatment of premenopausal osteoporosis"</a>.)</p><p class="headingAnchor" id="H3546459619"><span class="h3">Is there a preferred agent for osteoporosis in premenopausal patients with early breast cancer?</span><span class="headingEndMark"> — </span>For premenopausal patients with indications for a pharmacologic intervention to preserve bone mass and decrease the risk of osteoporotic fracture, data from small trials are available to support the use of various bisphosphonates (eg, <a class="drug drug_general" data-topicid="8774" href="/z/d/drug information/8774.html" rel="external">clodronate</a>, <a class="drug drug_general" data-topicid="10242" href="/z/d/drug information/10242.html" rel="external">risedronate</a>, <a class="drug drug_general" data-topicid="9736" href="/z/d/drug information/9736.html" rel="external">pamidronate</a>, and <a class="drug drug_general" data-topicid="9902" href="/z/d/drug information/9902.html" rel="external">zoledronic acid</a>) in the management of bone loss from cancer treatment-related amenorrhea [<a href="#rid12">12,20-22</a>].<a class="drug drug_general" data-topicid="15575" href="/z/d/drug information/15575.html" rel="external">Denosumab</a> (60 mg subcutaneously every six months) is not labeled for use in premenopausal women.</p><p>Data illustrating a positive impact on BMD in young women with breast cancer include the CALGB trial 79809. Among 150 premenopausal women with stage I to III breast cancer who had chemotherapy-induced ovarian failure, those assigned to <a class="drug drug_general" data-topicid="9902" href="/z/d/drug information/9902.html" rel="external">zoledronic acid</a> experienced increases in lumbar spine BMD at one year, versus those who had been observed during this time period (a 1.2 percent gain versus a 6.7 percent loss) [<a href="#rid23">23</a>]. The majority of zoledronic acid-related toxicities were mild (grade 1/2); grade 3 toxicities included fatigue, arthralgias, and bone pain in 1, 2, and 8 percent of women, respectively. There were no cases of osteonecrosis of the jaw or serious renal toxicity.</p><p>Similar results were seen in a substudy of the ABCSG-12 trial, in which <a class="drug drug_general" data-topicid="9902" href="/z/d/drug information/9902.html" rel="external">zoledronic acid</a> stabilized BMD in premenopausal women receiving adjuvant <a class="drug drug_general" data-topicid="8500" href="/z/d/drug information/8500.html" rel="external">goserelin</a> and either <a class="drug drug_general" data-topicid="9972" href="/z/d/drug information/9972.html" rel="external">tamoxifen</a> or <a class="drug drug_general" data-topicid="8780" href="/z/d/drug information/8780.html" rel="external">anastrozole</a> [<a href="#rid15">15,24</a>]. These data are discussed in more detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/2062.html" rel="external">"Evaluation and management of aromatase inhibitor-induced bone loss", section on 'Bone mineral density'</a>.)</p><p class="headingAnchor" id="H22072931"><span class="h2">Postmenopausal women</span><span class="headingEndMark"> — </span>Postmenopausal women with breast cancer may have a baseline risk of osteoporosis due to age and sex [<a href="#rid25">25,26</a>]. Data generated from the WHI-OS study demonstrated that women with a history of breast cancer diagnosed after the age of 55 have a higher risk of fractures than that of those without a history of breast cancer [<a href="#rid27">27</a>].</p><p>Chemotherapy and its associated supportive therapies may have a negative effect on BMD, although the direct effects of chemotherapy on the BMD of this population are not well established. Preliminary data suggest that women receiving adjuvant chemotherapy but not endocrine therapy may lose 1 to 10 percent of their bone mass within one year of chemotherapy [<a href="#rid28">28</a>].</p><p>While adjuvant <a class="drug drug_general" data-topicid="9972" href="/z/d/drug information/9972.html" rel="external">tamoxifen</a> in postmenopausal women can promote stabilization to mild increase in bone mass, most likely secondary to the end-organ specificity of this selective estrogen receptor modulator [<a href="#rid14">14,29</a>], endocrine therapy with an AI is associated with loss of BMD. Other risk factors for osteoporosis, as they relate to women with or without a history of breast cancer, are discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/2061.html" rel="external">"Osteoporotic fracture risk assessment", section on 'Clinical risk factor assessment'</a>.)</p><p class="headingAnchor" id="H3143834422"><span class="h3">Bisphosphonates and anti-RANK-ligand</span><span class="headingEndMark"> — </span>Interventions with a bisphosphonate or <a class="drug drug_general" data-topicid="15575" href="/z/d/drug information/15575.html" rel="external">denosumab</a> may be indicated to preserve bone mass and reduce risk of osteoporotic fractures in postmenopausal women treated for breast cancer [<a href="#rid3">3,4,30,31</a>]. This is of special relevance for women treated with an AI as they may experience a two- to fourfold increase in the rate of bone loss over the expected physiologic rate [<a href="#rid31">31</a>].</p><p>In several randomized trials, bisphosphonates prevented or reduced bone loss in women receiving AIs, but none of the trials were designed or powered to assess fractures as a primary outcome. These data are discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/2062.html" rel="external">"Evaluation and management of aromatase inhibitor-induced bone loss", section on 'Bisphosphonates'</a>.)</p><p><a class="drug drug_general" data-topicid="15575" href="/z/d/drug information/15575.html" rel="external">Denosumab</a> has also been shown to improve BMD in women receiving AIs, and has also been shown to reduce the risk of clinical fractures compared with placebo (but it has not been compared with bisphosphonates). These data are discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/2062.html" rel="external">"Evaluation and management of aromatase inhibitor-induced bone loss", section on 'Denosumab'</a>.)</p><p>Data regarding <a class="drug drug_general" data-topicid="15575" href="/z/d/drug information/15575.html" rel="external">denosumab</a> for osteoporosis among the general population are discussed elsewhere. </p><p><a class="drug drug_general" data-topicid="15575" href="/z/d/drug information/15575.html" rel="external">Denosumab</a> has been associated with an increased risk for vertebral fractures after discontinuation. Strategies to address this risk are discussed elsewhere and include use of a bisphosphonate upon stopping denosumab [<a href="#rid32">32,33</a>]. The optimal management of bone health after denosumab exposure continues to be an area of investigation. (See  <a class="medical medical_review" href="/z/d/html/2067.html" rel="external">"Denosumab for osteoporosis", section on 'Increased vertebral fractures'</a> and  <a class="medical medical_review" href="/z/d/html/2067.html" rel="external">"Denosumab for osteoporosis", section on 'Sequential osteoporosis therapy'</a>.)</p><p class="headingAnchor" id="H3202967975"><span class="h3">Is there a preferred agent for prevention and treatment of osteoporosis in postmenopausal patients with early breast cancer?</span><span class="headingEndMark"> — </span>For postmenopausal patients who warrant a pharmacologic intervention to preserve bone mass and decrease the risk of osteoporotic fracture, any one of several oral or intravenous bisphosphonates, or <a class="drug drug_general" data-topicid="15575" href="/z/d/drug information/15575.html" rel="external">denosumab</a>, may be used. This approach is discussed in more detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/2067.html" rel="external">"Denosumab for osteoporosis"</a> and  <a class="medical medical_review" href="/z/d/html/2064.html" rel="external">"Overview of the management of low bone mass and osteoporosis in postmenopausal women", section on 'Selection of oral bisphosphonate (usually preferred)'</a>.)</p><p class="headingAnchor" id="H1885057999"><span class="h2">Agents typically not used for osteoporosis in those with early-stage breast cancer</span></p><p class="headingAnchor" id="H2192794091"><span class="h3">Exogenous estrogens</span><span class="headingEndMark"> — </span>Hormonal therapies are generally avoided in patients with hormonally driven cancers [<a href="#rid4">4</a>]. Other classes of drugs to prevent or treat osteoporosis are favored.</p><p class="headingAnchor" id="H303280875"><span class="h3">Parathyroid hormone</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="10178" href="/z/d/drug information/10178.html" rel="external">Teriparatide</a> (parathyroid hormone [PTH] 1-34) and <a class="drug drug_general" data-topicid="112992" href="/z/d/drug information/112992.html" rel="external">abaloparatide</a> (PTH-related protein [PTHrP] 1-34) are anabolic osteoporosis agents that increase bone formation. However, teriparatide and abaloparatide are generally not favored for used in breast cancer. The FDA label of both PTH products warns that patients with bone metastases or prior radiation therapy should not be treated with these therapies. Although there are no known bone metastases when treating in the adjuvant setting, women with early-stage breast cancer are at risk of occult bone metastases and may have occult disseminated tumor cells within the bone marrow. There is theoretical concern that the PTH stimulation may promote growth of breast cancer cells in the bone microenvironment [<a href="#rid34">34,35</a>]. In addition, therapy with either PTH agents raises concern for risk of osteosarcoma [<a href="#rid36">36,37</a>]. (See  <a class="medical medical_review" href="/z/d/html/2057.html" rel="external">"Parathyroid hormone/parathyroid hormone-related protein analog therapy for osteoporosis", section on 'Long-term risks'</a>.)</p><p><a class="drug drug_general" data-topicid="120976" href="/z/d/drug information/120976.html" rel="external">Romosozumab</a> is another anabolic osteoporosis agent. It is a humanized monoclonal antibody that binds to sclerostin but does not have safety data in women with a history of breast cancer. (See  <a class="medical medical_review" href="/z/d/html/2064.html" rel="external">"Overview of the management of low bone mass and osteoporosis in postmenopausal women", section on 'Romosozumab'</a>.)</p><p class="headingAnchor" id="H203227933"><span class="h1">ADJUVANT BONE-MODIFYING TREATMENT FOR HIGHER-RISK BREAST CANCERS</span></p><p class="headingAnchor" id="H3919180637"><span class="h2">Bisphosphonates for anticancer therapy</span></p><p class="headingAnchor" id="H3471846767"><span class="h3">Efficacy</span><span class="headingEndMark"> — </span>In an EBCTCG patient-level meta-analysis of 26 clinical trials, treatment with bisphosphonates (<a class="drug drug_general" data-topicid="9427" href="/z/d/drug information/9427.html" rel="external">alendronate</a>, <a class="drug drug_general" data-topicid="8774" href="/z/d/drug information/8774.html" rel="external">clodronate</a>, <a class="drug drug_general" data-topicid="8887" href="/z/d/drug information/8887.html" rel="external">ibandronate</a>, <a class="drug drug_general" data-topicid="9736" href="/z/d/drug information/9736.html" rel="external">pamidronate</a>, <a class="drug drug_general" data-topicid="10242" href="/z/d/drug information/10242.html" rel="external">risedronate</a>, or <a class="drug drug_general" data-topicid="9902" href="/z/d/drug information/9902.html" rel="external">zoledronic acid</a>) led to borderline significance in improvements in recurrence, distant recurrence, and breast cancer mortality in postmenopausal women with early-stage breast cancer. The reduction in bone recurrence was modest but more definite (7.8 versus 9.0 percent; relative risk 0.83, 95% CI 0.73-0.94). Among postmenopausal women, bisphosphonate treatment resulted in statistically significant reductions in bone recurrence (6.6 versus 8.8 percent), fracture rates (0.1 versus 10.3 percent), breast cancer mortality (14.7 versus 18.0 percent) and overall survival (OS; 21.1 versus 23.5 percent) [<a href="#rid38">38</a>]. These benefits were not observed among premenopausal women. Most patients in this meta-analysis (83 percent) had received adjuvant chemotherapy, and bisphosphonate treatment was initiated shortly after surgery or chemotherapy.</p><p>Similar findings were seen in subsequent meta-analyses [<a href="#rid39">39,40</a>]. Other studies have shown mixed results [<a href="#rid41">41-43</a>], for example one meta-analysis failing to show statistically significant improvements in breast cancer recurrence or breast cancer mortality [<a href="#rid41">41</a>], and another demonstrating improvements in OS and fracture risk but not frequency of bone metastases or progression-free survival [<a href="#rid42">42</a>].</p><p>These data have impacted guideline recommendations for postmenopausal women with early-stage breast cancer [<a href="#rid3">3,44</a>]. However, universal use of adjuvant bisphosphonate therapy in postmenopausal women with early stage breast cancer has been questioned. Indeed, thought leaders have proposed adjuvant bisphosphonate use be reserved only for those postmenopausal women with a very high risk for recurrence [<a href="#rid45">45</a>].</p><p class="headingAnchor" id="H3687686544"><span class="h3">Patient selection</span><span class="headingEndMark"> — </span>For postmenopausal women (naturally, surgically, or chemically induced) with a moderate to high risk of distant recurrence (10 percent or higher) receiving any form of adjuvant systemic therapy, we suggest adjuvant bisphosphonates  (<a class="graphic graphic_algorithm graphicRef138606" href="/z/d/graphic/138606.html" rel="external">algorithm 1</a>). Although there are clear indications for osteoclast inhibitors for those with decreased bone mineral density and risk for fracture [<a href="#rid3">3,4,17,30</a>], their value in improving breast cancer outcomes and their acceptance for this use by clinicians and patients continues to evolve [<a href="#rid46">46-48</a>].</p><p>In weighing the pros and cons of adjuvant bisphosphonate therapy with the patient, factors to consider include the overall risk of breast cancer recurrence, the risk of side effects, financial toxicity, drug availability, patient preferences, comorbidities, and life expectancy [<a href="#rid44">44</a>]. Although the data do not yet provide a means to identify those most likely to benefit from adjuvant bisphosphonate therapy, some experts have expressed the view that therapy should be reserved for those considered to be at high risk of breast cancer recurrence (10 percent or higher) [<a href="#rid45">45,47,49,50</a>]. The online tool, <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fbreast.predict.nhs.uk%2F&amp;token=ktJxJWFyo6TX%2B3OPT%2FtieVv8LEH1afMscAzXSqUKz184T3jx7l4QDZ%2FUJBISMxSW&amp;TOPIC_ID=776" target="_blank">NHS PREDICT</a>, can help estimate the potential benefit from the use of an adjuvant bisphosphonate.</p><p>We note that the data in support of adjuvant bisphosphonates were generated using subset analysis, the biologic mechanism by which this subset benefits is not yet defined, and that the absolute anticancer benefits of adjuvant bisphosphonate therapy are likely to be small (meta-analyses have suggested an approximate 2 to 3 percent breast cancer mortality benefit [<a href="#rid38">38,51,52</a>]). As such, some patients or clinicians may reasonably opt not to consider this treatment given the potential for toxicity and concerns about modest efficacy.</p><p class="headingAnchor" id="H2095962927"><span class="h3">Choice of bisphosphonate for anticancer therapy</span><span class="headingEndMark"> — </span>Different osteoclast inhibitors are available worldwide, including oral and intravenous (IV) formulations  (<a class="graphic graphic_algorithm graphicRef138606" href="/z/d/graphic/138606.html" rel="external">algorithm 1</a>). When an adjuvant bisphosphonate is indicated, we suggest <a class="drug drug_general" data-topicid="9902" href="/z/d/drug information/9902.html" rel="external">zoledronic acid</a> or <a class="drug drug_general" data-topicid="8774" href="/z/d/drug information/8774.html" rel="external">clodronate</a> (although clodronate is not available in the United States), and consider oral <a class="drug drug_general" data-topicid="8887" href="/z/d/drug information/8887.html" rel="external">ibandronate</a> a less favored option (as there are no direct data supporting a disease-free survival (DFS) benefit with this agent). However, available data suggest that there are no survival advantages associated with one of these bisphosphonates over another [<a href="#rid44">44,53</a>]. There is insufficient evidence to support adjuvant <a class="drug drug_general" data-topicid="9427" href="/z/d/drug information/9427.html" rel="external">alendronate</a> or <a class="drug drug_general" data-topicid="10242" href="/z/d/drug information/10242.html" rel="external">risedronate</a> in regards to their potential anticancer efficacy. Access to adjuvant bisphosphonate therapy may limit the choice of therapy. (See <a class="local">'Dosing and duration'</a> below.)</p><p>In SWOG 0307, over 6000 women with stage I to III breast cancer (58 percent of whom were post-menopausal or over 50 years) who were treated with adjuvant systemic therapy were randomly assigned to <a class="drug drug_general" data-topicid="8774" href="/z/d/drug information/8774.html" rel="external">clodronate</a> (1600 mg orally) or <a class="drug drug_general" data-topicid="8887" href="/z/d/drug information/8887.html" rel="external">ibandronate</a> (50 mg orally) daily for three years, or <a class="drug drug_general" data-topicid="9902" href="/z/d/drug information/9902.html" rel="external">zoledronic acid</a> (4 mg IV every month for six months then every three months for 2.5 years) [<a href="#rid53">53</a>]. Five-year DFS rates were similar in each arm (88, 88, and 87 percent for clodronate, zoledronic acid, and ibandronate, respectively), with OS rates of 93 percent in the zoledronic acid and ibandronate arms and 92 percent in the clodronate arm. Ibandronate led to more grade 3/4 toxicities compared with either clodronate or zoledronic acid (10.5 versus 8 and 9 percent, respectively), but zoledronic acid resulted in higher rates of osteonecrosis of the jaw relative to ibandronate and clodronate (1.3 versus 0.8 and 0.4 percent, respectively). Notably, prior to treatment assignment, an overwhelming majority of patients (73 percent) indicated a preference for oral therapy rather than IV treatment if the agents were equally efficacious.</p><p>While SWOG 0307 demonstrated similar DFS between <a class="drug drug_general" data-topicid="8774" href="/z/d/drug information/8774.html" rel="external">clodronate</a>, <a class="drug drug_general" data-topicid="8887" href="/z/d/drug information/8887.html" rel="external">ibandronate</a>, and <a class="drug drug_general" data-topicid="9902" href="/z/d/drug information/9902.html" rel="external">zoledronic acid</a>, two separate trials evaluating ibandronate versus control have not demonstrated DFS benefits with oral ibandronate versus control either in postmenopausal women (GAIN/TEAM-IIB) [<a href="#rid43">43,54</a>] or in premenopausal patients (GAIN) [<a href="#rid54">54</a>]. Thus, when considering which adjuvant bisphosphonate to use, ibandronate does not have direct evidence to support impacting DFS and is the least favored option.</p><p class="headingAnchor" id="H786937593"><span class="h3">Dosing and duration</span><span class="headingEndMark"> — </span>When an adjuvant bisphosphonate is to be used, the strongest data are in <a class="drug drug_general" data-topicid="8774" href="/z/d/drug information/8774.html" rel="external">clodronate</a> and <a class="drug drug_general" data-topicid="9902" href="/z/d/drug information/9902.html" rel="external">zoledronic acid</a>. In our practice, we only have access to zoledronic acid. Zoledronic acid 4 mg IV is started within the typical adjuvant window that ranges from neoadjuvant therapy into three to six months after surgery. This is consistent with expert guidelines that support early initiation of bisphosphonate therapy [<a href="#rid44">44</a>].</p><p>As with bisphosphonate therapy for any indication, pretherapy attention is to be paid to oral health, electrolytes, and organ function, with particular attention to renal and gastrointestinal function, pending the route of bisphosphonate administration.</p><p>Guidelines from expert groups generally favor the incorporation of adjuvant bisphosphonates at higher doses than typical osteoporosis treatment. As examples:</p><p class="bulletIndent1"><span class="glyph">●</span>A consensus guideline from a European panel recommends the use of <a class="drug drug_general" data-topicid="9902" href="/z/d/drug information/9902.html" rel="external">zoledronic acid</a> 4 mg IV every six months or <a class="drug drug_general" data-topicid="8774" href="/z/d/drug information/8774.html" rel="external">clodronate</a> 1600 mg orally daily for three to five years in premenopausal women on adjuvant ovarian suppression and postmenopausal women at intermediate or high risk of recurrence [<a href="#rid55">55</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The American Society of Clinical Oncology (ASCO)-Ontario Health (OH, Cancer Care Ontario [CCO]) Clinical Practice Guideline advises the clinician to consider, when available, the use of either <a class="drug drug_general" data-topicid="9902" href="/z/d/drug information/9902.html" rel="external">zoledronic acid</a> 4 mg IV every six months or <a class="drug drug_general" data-topicid="8774" href="/z/d/drug information/8774.html" rel="external">clodronate</a> 1600 mg daily orally as adjuvant therapy for postmenopausal women deemed candidates for systemic adjuvant therapy [<a href="#rid51">51</a>]. The ASCO-OH (CCO) adds the options of zoledronic acid 4 mg every three months for two years, or <a class="drug drug_general" data-topicid="8887" href="/z/d/drug information/8887.html" rel="external">ibandronate</a> 50 mg daily for three years.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Guidelines from the European Society of Medical Oncology (ESMO) suggest that <a class="drug drug_general" data-topicid="9902" href="/z/d/drug information/9902.html" rel="external">zoledronic acid</a> 4 mg IV be used with chemotherapy, followed by either zoledronic acid or daily oral <a class="drug drug_general" data-topicid="8887" href="/z/d/drug information/8887.html" rel="external">ibandronate</a> or <a class="drug drug_general" data-topicid="8774" href="/z/d/drug information/8774.html" rel="external">clodronate</a> until 36 months [<a href="#rid3">3</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The National Comprehensive Cancer Network (NCCN) does not specify details of any particular regimen but notes that for risk reduction of distant metastasis consideration should be given to adjuvant bisphosphonate therapy for three to five years in postmenopausal patients (natural or induced) with high-risk node-negative or node-positive tumors [<a href="#rid56">56</a>].</p><p></p><p><a class="drug drug_general" data-topicid="9902" href="/z/d/drug information/9902.html" rel="external">Zoledronic acid</a> dosed at 4 mg has been investigated in a range of regimens in the adjuvant breast cancer setting. As examples of studies evaluating deintensified strategies:</p><p class="bulletIndent1"><span class="glyph">●</span>The SUCCESS A trial investigated two different regimens of adjuvant <a class="drug drug_general" data-topicid="9902" href="/z/d/drug information/9902.html" rel="external">zoledronic acid</a> [<a href="#rid57">57</a>]. The study included 2987 patients with early breast cancer, treated with two years of zoledronic acid 4 mg dosed every three months or a total of five years of zoledronic acid 4 mg, dosed initially every three months for the first two years followed by every six months dosing for the next three years. The two arms resulted in similar DFS (hazard ratio [HR] 0.97) and OS (HR 0.98) at a median of five years of follow-up [<a href="#rid57">57</a>]. Adverse events were more frequent in the five-year group (46 versus 27 percent). (See <a class="local">'Toxicity associated with osteoclast inhibitors'</a> below.)</p><p></p><p class="bulletIndent1">It has been noted that the SUCCESS A accrual was smaller than planned for this study and follow-up time was short. Nevertheless, the ASCO-OH (CCO) 2022 adjuvant bone modifying agent guideline update included the option of <a class="drug drug_general" data-topicid="9902" href="/z/d/drug information/9902.html" rel="external">zoledronic acid</a> 4 mg every three months for two years. In the SUCCESS A trial the shorter regimen treated for a total of 32 mg of zoledronic acid over two years versus the longer regimen which treated for a total of 56 mg of zoledronic acid over five years. These data suggest that a shorter duration of therapy, as well as a lower total dose of zoledronic acid was efficacious. A sub-study of the ABCSG-12 trial [<a href="#rid58">58</a>], analyzed whether the number of zoledronate infusions had an impact on breast cancer-specific outcomes and demonstrated no statistically significant difference in DFS or OS between those treated with six or less doses of zoledronic acid from those who were treated with seven or more doses of zoledronic acid. There is interest from both patients and providers to conduct studies with de-escalation of dosing [<a href="#rid47">47,48</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Similarly, in a substudy of a randomized trial (ABCSG-12), there was no statistically significant difference in DFS or OS in the patients who received ≤6 zoledronate infusions compared with those who received ≥7 zoledronate infusions [<a href="#rid58">58</a>].</p><p></p><p>The use of adjuvant bisphosphonates (either adjuvant <a class="drug drug_general" data-topicid="9902" href="/z/d/drug information/9902.html" rel="external">zoledronic acid</a> 4 mg IV or <a class="drug drug_general" data-topicid="8774" href="/z/d/drug information/8774.html" rel="external">clodronate</a> 1600 mg daily) may be logistically challenging because neither of these regimens is approved by the US Food and Drug Administration as an adjuvant cancer therapy.</p><p>Some have advocated that if a well-studied adjuvant bisphosphonate regimen is not accessible, then consideration may be given for the use of osteoporosis dosing of adjuvant bisphosphonates in postmenopausal women with a 10 percent or greater risk of distant recurrence [<a href="#rid49">49</a>]. It is of note that the EBCTCG meta-analysis did not identify a significant difference between dosing regimens or dosing frequency; however, there were insufficient numbers for assessment of osteoporosis dosing efficacy [<a href="#rid38">38</a>].</p><p class="headingAnchor" id="H2505538417"><span class="h2">Denosumab for anticancer therapy</span><span class="headingEndMark"> — </span>There are mixed data for efficacy of adjuvant <a class="drug drug_general" data-topicid="15575" href="/z/d/drug information/15575.html" rel="external">denosumab</a> in regards to improving DFS. However, because phase III trials suggest different outcomes in regards to DFS, and no trial has shown an OS benefit, we do not presently utilize denosumab for indications other than prevention or treatment of osteoporosis [<a href="#rid44">44,52,59</a>]. A more detailed review of denosumab for the management of aromatase inhibitor (AI)-induced bone loss is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/2062.html" rel="external">"Evaluation and management of aromatase inhibitor-induced bone loss"</a> and  <a class="medical medical_review" href="/z/d/html/2062.html" rel="external">"Evaluation and management of aromatase inhibitor-induced bone loss", section on 'Denosumab'</a>.)</p><p>The D-CARE trial enrolled 4500 patients with early-stage breast cancer (over one-half of whom were on AIs for hormone receptor-positive disease). The study drug was dosed as <a class="drug drug_general" data-topicid="15575" href="/z/d/drug information/15575.html" rel="external">denosumab</a> at 120 mg or matching placebo monthly for six months, then every three months for up to five years. Denosumab was associated with neither a bone metastasis-free benefit (HR 0.97 for denosumab versus placebo, respectively; 95% CI 0.82-1.14), nor a DFS benefit (HR 1.04, 95% CI 0.91-1.19) [<a href="#rid59">59,60</a>]. None of the subgroups identified (eg, premenopausal, postmenopausal, hormone receptor-positive or negative disease) experienced benefits in these outcomes. The frequency of osteonecrosis of the jaw was higher among those receiving denosumab (5.4 versus 0.2 percent, respectively), as were atypical femur fractures, though the rates were low in both groups (0.4 versus 0.0 percent, respectively).</p><p>The ABCSG-18 trial assessed DFS in 3400 postmenopausal women on AIs for hormone receptor-positive breast cancer randomly assigned to <a class="drug drug_general" data-topicid="15575" href="/z/d/drug information/15575.html" rel="external">denosumab</a> 60 mg every six months or placebo. The primary endpoint of the study was clinical fracture. Secondary endpoints of this study include disease-related outcomes. At a median follow-up of six years, denosumab was associated with improved DFS (287 versus 240 DFS events; HR 0.82, 95% CI 0.69-0.98) [<a href="#rid52">52</a>]. With longer follow-up (median eight years), denosumab resulted in a 3.5 percent improvement in nine-year DFS (79.4 versus 75.9 percent, HR 0.83, 95% CI 0.71-0.97) [<a href="#rid61">61</a>]. Bone metastasis free survival was 89 versus 86 percent (HR 0.81, 95% CI 0.65-1.00) and OS was 91 versus 90 percent, respectively (HR 0.80, 95% CI 0.64-1.01), but these differences were not statistically significant. There were no cases of osteonecrosis of the jaw and one potential case of an atypical femoral fracture.</p><p>At present, ASCO–OH (CCO), ESMO, and NCCN do not provide recommendations for use of adjuvant <a class="drug drug_general" data-topicid="15575" href="/z/d/drug information/15575.html" rel="external">denosumab</a> as an anticancer intervention.</p><p>Use of <a class="drug drug_general" data-topicid="15575" href="/z/d/drug information/15575.html" rel="external">denosumab</a> for therapy-related bone loss is discussed above. (See <a class="local">'Bisphosphonates and anti-RANK-ligand'</a> above.)</p><p class="headingAnchor" id="H9"><span class="h1">TOXICITY ASSOCIATED WITH OSTEOCLAST INHIBITORS</span><span class="headingEndMark"> — </span>Therapy with an osteoclast inhibitor, whether for osteoporosis management or as an adjuvant therapy is generally well tolerated. However, both the bisphosphonates and <a class="drug drug_general" data-topicid="15575" href="/z/d/drug information/15575.html" rel="external">denosumab</a> are associated with the risk of developing electrolyte disturbance (most notably hypocalcemia), atypical fractures, and osteonecrosis of the jaw or atypical fracture of the jaw.</p><p>The intravenous bisphosphonates also may associate with acute phase reactions, renal toxicity, and rarely, ocular inflammation [<a href="#rid62">62</a>], while the oral bisphosphonates may have gastrointestinal side effects. (See  <a class="medical medical_review" href="/z/d/html/96863.html" rel="external">"Medication-related osteonecrosis of the jaw in patients with cancer", section on 'Osteoclast inhibitor therapy'</a> and  <a class="medical medical_review" href="/z/d/html/2806.html" rel="external">"Risks of therapy with bone antiresorptive agents in patients with advanced malignancy"</a> and  <a class="medical medical_review" href="/z/d/html/104424.html" rel="external">"Risks of bisphosphonate therapy in patients with osteoporosis"</a>.)</p><p><a class="drug drug_general" data-topicid="15575" href="/z/d/drug information/15575.html" rel="external">Denosumab</a> may specifically associate with infection and dermatologic reactions. Denosumab, upon discontinuation, may be associated with an increased risk of vertebral fracture, and means to reduce this risk are under investigation [<a href="#rid32">32,63</a>]. This is discussed in detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/2067.html" rel="external">"Denosumab for osteoporosis", section on 'Increased vertebral fractures'</a> and  <a class="medical medical_review" href="/z/d/html/2067.html" rel="external">"Denosumab for osteoporosis", section on 'Sequential osteoporosis therapy'</a>.)</p><p>The incidence of osteonecrosis of the jaw with bisphosphonates or <a class="drug drug_general" data-topicid="15575" href="/z/d/drug information/15575.html" rel="external">denosumab</a> for osteoporosis treatment or prevention, as well as adjuvant anticancer therapy, appears to be uncommon. With the bisphosphonate studies, the incidence is approximately 0.7 percent [<a href="#rid64">64,65</a>]. A joint guideline from multiple expert groups provides recommendations on oral care and reducing the risk of osteonecrosis of the jaw [<a href="#rid66">66</a>]. Further discussion on the risks of therapy and recommendations for monitoring are provided separately. (See  <a class="medical medical_review" href="/z/d/html/2806.html" rel="external">"Risks of therapy with bone antiresorptive agents in patients with advanced malignancy", section on 'Osteonecrosis of the jaw'</a>.)</p><p>Of particular importance to premenopausal women are the safety data regarding future pregnancy after bisphosphonate, as the drug may leach from bone over time. (See  <a class="medical medical_review" href="/z/d/html/2060.html" rel="external">"Evaluation and treatment of premenopausal osteoporosis", section on 'Antiresorptive therapy with bisphosphonates'</a>.)</p><p class="headingAnchor" id="H1454438147"><span class="h1">CAUTION IS TO BE TAKEN IN WOMEN WITH A HISTORY OF BREAST CANCER</span><span class="headingEndMark"> — </span>It is of note that not all pharmacologic interventions available for management of bone health are appropriate for patients with a history of breast cancer. In general, the estrogen-like, estrogen-progesterone, and parathyroid hormone therapies are not favored in patients with a history of breast cancer as there is theoretical concern regarding the potential to stimulate growth of occult tumor cells and to negatively impact cancer outcomes [<a href="#rid4">4,33,67-69</a>]. The sclerostin-targeting therapy, <a class="drug drug_general" data-topicid="120976" href="/z/d/drug information/120976.html" rel="external">romosozumab</a>, does not have safety data specific to the breast cancer population.</p><p>All drugs used in patients of childbearing potential need to be considered for safety if family planning and lactation has not been completed.</p><p>The selective estrogen receptor modulators, such as <a class="drug drug_general" data-topicid="9972" href="/z/d/drug information/9972.html" rel="external">tamoxifen</a> or <a class="drug drug_general" data-topicid="9593" href="/z/d/drug information/9593.html" rel="external">raloxifene</a>, are generally not to be used concurrently with an aromatase inhibitor (AI) in a patient with estrogen receptor-positive breast cancer since the combined use of tamoxifen and an AI was not better than tamoxifen alone, in regards to breast cancer outcomes, in a randomized trial [<a href="#rid70">70</a>].</p><p class="headingAnchor" id="H2132431814"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/113775.html" rel="external">"Society guideline links: Breast cancer"</a>.)</p><p class="headingAnchor" id="H10"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Introduction</strong> – Osteoclast inhibitors reduce the risk of osteoporosis and fractures. They have also been evaluated as anticancer treatments in the adjuvant setting to improve breast cancer outcomes. (See <a class="local">'Introduction'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>General measures</strong> – Breast cancer therapy-related bone loss prevention and treatment of osteoporosis and osteopenia should be addressed initially with adequate nutrition (calcium and vitamin D), regular weight-bearing exercise, and healthy lifestyle behaviors. Those at higher risk of osteoporosis and fracture may be candidates for therapy with a bisphosphonate or <a class="drug drug_general" data-topicid="15575" href="/z/d/drug information/15575.html" rel="external">denosumab</a>. (See <a class="local">'General measures'</a> above and  <a class="medical medical_review" href="/z/d/html/2064.html" rel="external">"Overview of the management of low bone mass and osteoporosis in postmenopausal women", section on 'Lifestyle measures to reduce bone loss'</a> and  <a class="medical medical_review" href="/z/d/html/2064.html" rel="external">"Overview of the management of low bone mass and osteoporosis in postmenopausal women", section on 'Patient selection'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Causes of bone loss in patients with breast cancer</strong> – Bone loss may be accelerated in premenopausal women secondary to factors that decrease ovarian estrogen, such as oophorectomy, chemotherapy-induced ovarian dysfunction, or with ovarian suppression due to adjuvant endocrine therapy (eg, gonadotropin-releasing hormone agonists). Accelerated bone loss may occur in postmenopausal women treated with an aromatase inhibitor. <a class="drug drug_general" data-topicid="9972" href="/z/d/drug information/9972.html" rel="external">Tamoxifen</a> with its agonist-antagonist effects is associated with bone mineral density (BMD) loss in premenopausal women and BMD stability or gain in postmenopausal women. (See <a class="local">'Treatment for breast cancer therapy-associated bone loss'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Screening and risk assessment for bone loss</strong> – Screening for fracture risk includes history, physical exam, and, in some cases, dual-energy x-ray absorptiometry (DXA) or other validated tool for fracture risk prediction. Further details on screening and risk assessment are discussed elsewhere. (See <a class="local">'Premenopausal women'</a> above and <a class="local">'Postmenopausal women'</a> above and  <a class="medical medical_review" href="/z/d/html/2046.html" rel="external">"Screening for osteoporosis in postmenopausal women and men", section on 'Fracture risk assessment'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Osteoclast inhibitors for bone density loss and reducing the risk of fracture</strong> – For women found to have osteoporosis based upon a DXA scan (T score of -2.5 or lower or a history of fracture due to low BMD), or osteopenia with additional risk of fracture, we use an osteoclast inhibitor, similar to the approach adopted for those without a history of cancer. Additionally, we provide counseling on nutritional, exercise, and healthy lifestyle behavior. Further details on screening and risk assessment are discussed elsewhere. (See <a class="local">'Premenopausal women'</a> above and <a class="local">'Postmenopausal women'</a> above and  <a class="medical medical_review" href="/z/d/html/2064.html" rel="external">"Overview of the management of low bone mass and osteoporosis in postmenopausal women"</a> and  <a class="medical medical_review" href="/z/d/html/2060.html" rel="external">"Evaluation and treatment of premenopausal osteoporosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Bisphosphonates for anticancer therapy</strong> – For postmenopausal women (naturally, surgically, or chemically induced) with a moderate to high risk of distant recurrence (10 percent or higher) receiving any form of adjuvant systemic therapy, we suggest adjuvant bisphosphonates  (<a class="graphic graphic_algorithm graphicRef138606" href="/z/d/graphic/138606.html" rel="external">algorithm 1</a>) (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). However, the absolute benefits of adjuvant bisphosphonate therapy are likely to be small, and some patients and clinicians may opt not to consider this treatment given the potential for toxicity and concerns about modest efficacy. The NHS PREDICT tool online may inform the doctor-patient discussion on the potential benefit of adjuvant bisphosphonate therapy. (See <a class="local">'Bisphosphonates for anticancer therapy'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>While <a class="drug drug_general" data-topicid="15575" href="/z/d/drug information/15575.html" rel="external">denosumab</a> is an option for reducing the risk of osteoporosis and fracture, trials of adjuvant denosumab show conflicting results in regards to disease-free survival (DFS), and no trial has shown an uncensored statistically significant overall survival benefit. Therefore, based on available data, we do not utilize denosumab for indications other than bone health. (See <a class="local">'Denosumab for anticancer therapy'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Choice of agent</strong> – In postmenopausal women receiving adjuvant bisphosphonates, we suggest <a class="drug drug_general" data-topicid="9902" href="/z/d/drug information/9902.html" rel="external">zoledronic acid</a> or <a class="drug drug_general" data-topicid="8774" href="/z/d/drug information/8774.html" rel="external">clodronate</a> (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>), and consider oral <a class="drug drug_general" data-topicid="8887" href="/z/d/drug information/8887.html" rel="external">ibandronate</a> a less favored alternative (as there are no direct data supporting a DFS benefit with this agent). Present international guidelines recommend use of zoledronic acid 4 mg intravenously every six months for three to five years, zoledronic acid 4 mg intravenously every three months for two years, clodronate 1600 mg orally daily for two to three years, or ibandronate 50 mg orally daily for three years.</p><p></p><p class="bulletIndent1">The doses of <a class="drug drug_general" data-topicid="9902" href="/z/d/drug information/9902.html" rel="external">zoledronic acid</a> and <a class="drug drug_general" data-topicid="8887" href="/z/d/drug information/8887.html" rel="external">ibandronate</a> are not the standard osteoporosis dose, and are not approved by the US Food and Drug Administration (FDA). <a class="drug drug_general" data-topicid="8774" href="/z/d/drug information/8774.html" rel="external">Clodronate</a> (at any dose) is not approved by the FDA, but is available outside of the United States.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Most studies started the bisphosphonate shortly after surgery or chemotherapy.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The side effects of therapy may be serious and include a low risk of osteonecrosis of the jaw or atypical fracture of the jaw. Other side effects include gastrointestinal, renal, and electrolyte disturbances as well as acute phase reactions. (See <a class="local">'Toxicity associated with osteoclast inhibitors'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li class="breakAll">SEER Stat Fact Sheets: Breast Cancer http://seer.cancer.gov/statfacts/html/breast.html (Accessed on April 15, 2019).</li><li><a class="nounderline abstract_t">Handforth C, D'Oronzo S, Coleman R, Brown J. Cancer Treatment and Bone Health. Calcif Tissue Int 2018; 102:251.</a></li><li><a class="nounderline abstract_t">Coleman R, Hadji P, Body JJ, et al. Bone health in cancer: ESMO Clinical Practice Guidelines. Ann Oncol 2020; 31:1650.</a></li><li><a class="nounderline abstract_t">Shapiro CL, Van Poznak C, Lacchetti C, et al. Management of Osteoporosis in Survivors of Adult Cancers With Nonmetastatic Disease: ASCO Clinical Practice Guideline. J Clin Oncol 2019; 37:2916.</a></li><li><a class="nounderline abstract_t">Hassett MJ, Somerfield MR, Baker ER, et al. Management of Male Breast Cancer: ASCO Guideline. J Clin Oncol 2020; 38:1849.</a></li><li class="breakAll">A Public Health Approach to Promote Bone Health. National Library of Medicine. Available at: https://www.ncbi.nlm.nih.gov/books/NBK45518/ (Accessed on March 03, 2023).</li><li><a class="nounderline abstract_t">Waqas K, Lima Ferreira J, Tsourdi E, et al. Updated guidance on the management of cancer treatment-induced bone loss (CTIBL) in pre- and postmenopausal women with early-stage breast cancer. J Bone Oncol 2021; 28:100355.</a></li><li><a class="nounderline abstract_t">Vehmanen L, Elomaa I, Blomqvist C, Saarto T. Tamoxifen treatment after adjuvant chemotherapy has opposite effects on bone mineral density in premenopausal patients depending on menstrual status. J Clin Oncol 2006; 24:675.</a></li><li><a class="nounderline abstract_t">Shapiro CL, Manola J, Leboff M. Ovarian failure after adjuvant chemotherapy is associated with rapid bone loss in women with early-stage breast cancer. J Clin Oncol 2001; 19:3306.</a></li><li><a class="nounderline abstract_t">Powles TJ, McCloskey E, Paterson AH, et al. Oral clodronate and reduction in loss of bone mineral density in women with operable primary breast cancer. J Natl Cancer Inst 1998; 90:704.</a></li><li><a class="nounderline abstract_t">Saarto T, Blomqvist C, Välimäki M, et al. Chemical castration induced by adjuvant cyclophosphamide, methotrexate, and fluorouracil chemotherapy causes rapid bone loss that is reduced by clodronate: a randomized study in premenopausal breast cancer patients. J Clin Oncol 1997; 15:1341.</a></li><li><a class="nounderline abstract_t">Delmas PD, Balena R, Confravreux E, et al. Bisphosphonate risedronate prevents bone loss in women with artificial menopause due to chemotherapy of breast cancer: a double-blind, placebo-controlled study. J Clin Oncol 1997; 15:955.</a></li><li><a class="nounderline abstract_t">Sverrisdóttir A, Fornander T, Jacobsson H, et al. Bone mineral density among premenopausal women with early breast cancer in a randomized trial of adjuvant endocrine therapy. J Clin Oncol 2004; 22:3694.</a></li><li><a class="nounderline abstract_t">Powles TJ, Hickish T, Kanis JA, et al. Effect of tamoxifen on bone mineral density measured by dual-energy x-ray absorptiometry in healthy premenopausal and postmenopausal women. J Clin Oncol 1996; 14:78.</a></li><li><a class="nounderline abstract_t">Gnant MF, Mlineritsch B, Luschin-Ebengreuth G, et al. Zoledronic acid prevents cancer treatment-induced bone loss in premenopausal women receiving adjuvant endocrine therapy for hormone-responsive breast cancer: a report from the Austrian Breast and Colorectal Cancer Study Group. J Clin Oncol 2007; 25:820.</a></li><li><a class="nounderline abstract_t">Kim M, Kim H, Ahn SH, et al. Changes in bone mineral density during 5 years of adjuvant treatment in premenopausal breast cancer patients. Breast Cancer Res Treat 2020; 180:657.</a></li><li><a class="nounderline abstract_t">Reid DM, Doughty J, Eastell R, et al. Guidance for the management of breast cancer treatment-induced bone loss: a consensus position statement from a UK Expert Group. Cancer Treat Rev 2008; 34 Suppl 1:S3.</a></li><li><a class="nounderline abstract_t">Favus MJ. Bisphosphonates for osteoporosis. N Engl J Med 2010; 363:2027.</a></li><li><a class="nounderline abstract_t">Body JJ. Prevention and treatment of side-effects of systemic treatment: bone loss. Ann Oncol 2010; 21 Suppl 7:vii180.</a></li><li><a class="nounderline abstract_t">Vehmanen L, Saarto T, Risteli J, et al. Short-term intermittent intravenous clodronate in the prevention of bone loss related to chemotherapy-induced ovarian failure. Breast Cancer Res Treat 2004; 87:181.</a></li><li><a class="nounderline abstract_t">Fuleihan Gel-H, Salamoun M, Mourad YA, et al. Pamidronate in the prevention of chemotherapy-induced bone loss in premenopausal women with breast cancer: a randomized controlled trial. J Clin Endocrinol Metab 2005; 90:3209.</a></li><li><a class="nounderline abstract_t">Vehmanen L, Saarto T, Elomaa I, et al. Long-term impact of chemotherapy-induced ovarian failure on bone mineral density (BMD) in premenopausal breast cancer patients. The effect of adjuvant clodronate treatment. Eur J Cancer 2001; 37:2373.</a></li><li><a class="nounderline abstract_t">Shapiro CL, Halabi S, Hars V, et al. Zoledronic acid preserves bone mineral density in premenopausal women who develop ovarian failure due to adjuvant chemotherapy: final results from CALGB trial 79809. Eur J Cancer 2011; 47:683.</a></li><li><a class="nounderline abstract_t">Gnant M, Mlineritsch B, Luschin-Ebengreuth G, et al. Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy. Lancet Oncol 2008; 9:840.</a></li><li><a class="nounderline abstract_t">Raisz LG. Clinical practice. Screening for osteoporosis. N Engl J Med 2005; 353:164.</a></li><li><a class="nounderline abstract_t">Rosen CJ. Clinical practice. Postmenopausal osteoporosis. N Engl J Med 2005; 353:595.</a></li><li><a class="nounderline abstract_t">Chen Z, Maricic M, Bassford TL, et al. Fracture risk among breast cancer survivors: results from the Women's Health Initiative Observational Study. Arch Intern Med 2005; 165:552.</a></li><li><a class="nounderline abstract_t">Van Poznak C, Morris P, D'Andrea G, et al. Bone Mineral Density (BMD) Changes at 1 Year in Postmenopausal Women Who Are Not Receiving Adjuvant Endocrine Therapy for Breast Cancer (BCA). Cancer Res 2009; 69S: SABCS #1066.</a></li><li><a class="nounderline abstract_t">Love RR, Mazess RB, Barden HS, et al. Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer. N Engl J Med 1992; 326:852.</a></li><li><a class="nounderline abstract_t">Gralow JR, Biermann JS, Farooki A, et al. NCCN Task Force Report: Bone Health In Cancer Care. J Natl Compr Canc Netw 2013; 11 Suppl 3:S1.</a></li><li><a class="nounderline abstract_t">Hadji P, Aapro MS, Body JJ, et al. Management of Aromatase Inhibitor-Associated Bone Loss (AIBL) in postmenopausal women with hormone sensitive breast cancer: Joint position statement of the IOF, CABS, ECTS, IEG, ESCEO IMS, and SIOG. J Bone Oncol 2017; 7:1.</a></li><li><a class="nounderline abstract_t">Tsourdi E, Zillikens MC, Meier C, et al. Fracture risk and management of discontinuation of denosumab therapy: a systematic review and position statement by ECTS. J Clin Endocrinol Metab 2020.</a></li><li><a class="nounderline abstract_t">Khan MI. Management of bone loss due to endocrine therapy during cancer treatment. Osteoporos Int 2023; 34:671.</a></li><li><a class="nounderline abstract_t">Tjensvoll K, Nordgård O, Skjæveland M, et al. Detection of disseminated tumor cells in bone marrow predict late recurrences in operable breast cancer patients. BMC Cancer 2019; 19:1131.</a></li><li><a class="nounderline abstract_t">Taxel P, Faircloth E, Idrees S, Van Poznak C. Cancer Treatment-Induced Bone Loss in Women With Breast Cancer and Men With Prostate Cancer. J Endocr Soc 2018; 2:574.</a></li><li class="breakAll">Teriparatide (rDNA origin) injection. United States Prescribing Information. US National Library of Medicine. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/021318s053lbl.pdf (Accessed on April 25, 2022).</li><li class="breakAll">Abaloparatide injection. United States Prescribing Information. US National Library of Medicine. https://radiuspharm.com/wp-content/uploads/tymlos/tymlos-prescribing-information.pdf (Accessed on April 25, 2022).</li><li><a class="nounderline abstract_t">Early Breast Cancer Trialists' Collaborative Group (EBCTCG), Coleman R, Powles T, et al. Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials. Lancet 2015; 386:1353.</a></li><li><a class="nounderline abstract_t">O'Carrigan B, Wong MH, Willson ML, et al. Bisphosphonates and other bone agents for breast cancer. Cochrane Database Syst Rev 2017; 10:CD003474.</a></li><li><a class="nounderline abstract_t">Wang SF, Lin YS, Yeh WY, et al. The Clinical Benefits of Antiresorptive Agents in Patients with Primary Breast Cancer Receiving Adjuvant Endocrine Therapy: A Systematic Review with Pairwise and Network Meta-analysis. J Clin Endocrinol Metab 2023; 108:e1433.</a></li><li><a class="nounderline abstract_t">Mauri D, Valachis A, Polyzos NP, et al. Does adjuvant bisphosphonate in early breast cancer modify the natural course of the disease? A meta-analysis of randomized controlled trials. J Natl Compr Canc Netw 2010; 8:279.</a></li><li><a class="nounderline abstract_t">Valachis A, Polyzos NP, Coleman RE, et al. Adjuvant therapy with zoledronic acid in patients with breast cancer: a systematic review and meta-analysis. Oncologist 2013; 18:353.</a></li><li><a class="nounderline abstract_t">Vliek SB, Noordhoek I, Meershoek-Klein Kranenbarg E, et al. Daily Oral Ibandronate With Adjuvant Endocrine Therapy in Postmenopausal Women With Estrogen Receptor-Positive Breast Cancer (BOOG 2006-04): Randomized Phase III TEAM-IIB Trial. J Clin Oncol 2022; 40:2934.</a></li><li><a class="nounderline abstract_t">Eisen A, Somerfield MR, Accordino MK, et al. Use of Adjuvant Bisphosphonates and Other Bone-Modifying Agents in Breast Cancer: ASCO-OH (CCO) Guideline Update. J Clin Oncol 2022; 40:787.</a></li><li><a class="nounderline abstract_t">Desnoyers A, Amir E, Tannock IF. Adjuvant Zoledronate Therapy for Women With Breast Cancer-Effective Treatment or Fool's Gold? JAMA Oncol 2021; 7:1121.</a></li><li><a class="nounderline abstract_t">Jacobs C, Amir E, Paterson A, et al. Are adjuvant bisphosphonates now standard of care of women with early stage breast cancer? A debate from the Canadian Bone and the Oncologist New Updates meeting. J Bone Oncol 2015; 4:54.</a></li><li><a class="nounderline abstract_t">McGee S, Alzahrani M, Vandermeer L, et al. Adjuvant bisphosphonate use in patients with early stage breast cancer: a physician survey. Breast Cancer Res Treat 2021; 187:477.</a></li><li><a class="nounderline abstract_t">McGee S, AlZahrani M, Stober C, et al. Adjuvant bisphosphonate use in patients with early stage breast cancer: Patient perspectives on treatment acceptability and potential de-escalation. J Bone Oncol 2021; 27:100351.</a></li><li><a class="nounderline abstract_t">Stopeck AT. Osteoclast inhibition in postmenopausal breast cancer: Is the evidence too strong to ignore? Cancer 2017; 123:2392.</a></li><li class="breakAll">American Society of Clinical Oncology (ASCO). The ASCO Post: Denosumab prevents neither breast cancer relapse nor death. https://ascopost.com/issues/june-25-2019/denosumab-prevents-neither-breast-cancer-relapse-nor-death/.</li><li><a class="nounderline abstract_t">Dhesy-Thind S, Fletcher GG, Blanchette PS, et al. Use of Adjuvant Bisphosphonates and Other Bone-Modifying Agents in Breast Cancer: A Cancer Care Ontario and American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol 2017; 35:2062.</a></li><li><a class="nounderline abstract_t">Gnant M, Pfeiler G, Steger GG, et al. Adjuvant denosumab in postmenopausal patients with hormone receptor-positive breast cancer (ABCSG-18): disease-free survival results from a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 2019; 20:339.</a></li><li><a class="nounderline abstract_t">Gralow JR, Barlow WE, Paterson AHG, et al. Phase III Randomized Trial of Bisphosphonates as Adjuvant Therapy in Breast Cancer: S0307. J Natl Cancer Inst 2020; 112:698.</a></li><li><a class="nounderline abstract_t">von Minckwitz G, Möbus V, Schneeweiss A, et al. German adjuvant intergroup node-positive study: a phase III trial to compare oral ibandronate versus observation in patients with high-risk early breast cancer. J Clin Oncol 2013; 31:3531.</a></li><li><a class="nounderline abstract_t">Hadji P, Coleman RE, Wilson C, et al. Adjuvant bisphosphonates in early breast cancer: consensus guidance for clinical practice from a European Panel. Ann Oncol 2016; 27:379.</a></li><li class="breakAll">https://www.nccn.org/professionals/physician_gls/pdf/breast.pdf (Accessed on March 03, 2023).</li><li><a class="nounderline abstract_t">Friedl TWP, Fehm T, Müller V, et al. Prognosis of Patients With Early Breast Cancer Receiving 5 Years vs 2 Years of Adjuvant Bisphosphonate Treatment: A Phase 3 Randomized Clinical Trial. JAMA Oncol 2021; 7:1149.</a></li><li><a class="nounderline abstract_t">Beltran-Bless AA, Clemons MJ, Fesl C, et al. Does the number of 6-monthly adjuvant zoledronate infusions received affect treatment efficacy for early breast cancer? A sub-study of ABCSG-12. Eur J Cancer 2023; 180:108.</a></li><li><a class="nounderline abstract_t">Coleman RE, Finkelstein D, Barrios CH, et al. Adjuvant denosumab in early breast cancer: First results from the international multicenter randomized phase III placebo controlled D-CARE study. J Clin Oncol 2018; 36S: ASCO #501.</a></li><li><a class="nounderline abstract_t">Coleman R, Finkelstein DM, Barrios C, et al. Adjuvant denosumab in early breast cancer (D-CARE): an international, multicentre, randomised, controlled, phase 3 trial. Lancet Oncol 2020; 21:60.</a></li><li><a class="nounderline abstract_t">Gnant M, Frantal S, Pfeiler G, et al. Long-Term Outcomes of Adjuvant Denosumab in Breast Cancer. NEJM Evid 2022; 1(12).</a></li><li><a class="nounderline abstract_t">Clark EM, Durup D. Inflammatory eye reactions with bisphosphonates and other osteoporosis medications: what are the risks? Ther Adv Musculoskelet Dis 2015; 7:11.</a></li><li><a class="nounderline abstract_t">Cummings SR, Ferrari S, Eastell R, et al. Vertebral Fractures After Discontinuation of Denosumab: A Post Hoc Analysis of the Randomized Placebo-Controlled FREEDOM Trial and Its Extension. J Bone Miner Res 2018; 33:190.</a></li><li><a class="nounderline abstract_t">Mauri D, Valachis A, Polyzos IP, et al. Osteonecrosis of the jaw and use of bisphosphonates in adjuvant breast cancer treatment: a meta-analysis. Breast Cancer Res Treat 2009; 116:433.</a></li><li><a class="nounderline abstract_t">Rathbone EJ, Brown JE, Marshall HC, et al. Osteonecrosis of the jaw and oral health-related quality of life after adjuvant zoledronic acid: an adjuvant zoledronic acid to reduce recurrence trial subprotocol (BIG01/04). J Clin Oncol 2013; 31:2685.</a></li><li><a class="nounderline abstract_t">Yarom N, Shapiro CL, Peterson DE, et al. Medication-Related Osteonecrosis of the Jaw: MASCC/ISOO/ASCO Clinical Practice Guideline. J Clin Oncol 2019; 37:2270.</a></li><li><a class="nounderline abstract_t">Clines GA, Choksi P, Van Poznak C. Adjuvant Endocrine Therapy and Bone Health in Breast Cancer. Curr Osteoporos Rep 2015; 13:263.</a></li><li><a class="nounderline abstract_t">Cosman F, Crittenden DB, Adachi JD, et al. Romosozumab Treatment in Postmenopausal Women with Osteoporosis. N Engl J Med 2016; 375:1532.</a></li><li><a class="nounderline abstract_t">MacNabb C, Patton D, Hayes JS. Sclerostin Antibody Therapy for the Treatment of Osteoporosis: Clinical Prospects and Challenges. J Osteoporos 2016; 2016:6217286.</a></li><li><a class="nounderline abstract_t">Baum M, Budzar AU, Cuzick J, et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet 2002; 359:2131.</a></li></ol></div><div id="topicVersionRevision">Topic 776 Version 50.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="http://seer.cancer.gov/statfacts/html/breast.html" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : SEER Stat Fact Sheets: Breast Cancer http://seer.cancer.gov/statfacts/html/breast.html (Accessed on April 15, 2019).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29353450" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Cancer Treatment and Bone Health.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32801018" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Bone health in cancer: ESMO Clinical Practice Guidelines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31532726" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Management of Osteoporosis in Survivors of Adult Cancers With Nonmetastatic Disease: ASCO Clinical Practice Guideline.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32058842" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Management of Male Breast Cancer: ASCO Guideline.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32058842" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Management of Male Breast Cancer: ASCO Guideline.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33948427" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Updated guidance on the management of cancer treatment-induced bone loss (CTIBL) in pre- and postmenopausal women with early-stage breast cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16446340" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Tamoxifen treatment after adjuvant chemotherapy has opposite effects on bone mineral density in premenopausal patients depending on menstrual status.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11454877" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Ovarian failure after adjuvant chemotherapy is associated with rapid bone loss in women with early-stage breast cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9586668" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Oral clodronate and reduction in loss of bone mineral density in women with operable primary breast cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9193325" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Chemical castration induced by adjuvant cyclophosphamide, methotrexate, and fluorouracil chemotherapy causes rapid bone loss that is reduced by clodronate: a randomized study in premenopausal breast cancer patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9060533" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Bisphosphonate risedronate prevents bone loss in women with artificial menopause due to chemotherapy of breast cancer: a double-blind, placebo-controlled study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15365065" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Bone mineral density among premenopausal women with early breast cancer in a randomized trial of adjuvant endocrine therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8558225" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Effect of tamoxifen on bone mineral density measured by dual-energy x-ray absorptiometry in healthy premenopausal and postmenopausal women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17159195" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Zoledronic acid prevents cancer treatment-induced bone loss in premenopausal women receiving adjuvant endocrine therapy for hormone-responsive breast cancer: a report from the Austrian Breast and Colorectal Cancer Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32072339" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Changes in bone mineral density during 5 years of adjuvant treatment in premenopausal breast cancer patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18515009" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Guidance for the management of breast cancer treatment-induced bone loss: a consensus position statement from a UK Expert Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21083387" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Bisphosphonates for osteoporosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20943612" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Prevention and treatment of side-effects of systemic treatment: bone loss.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15377842" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Short-term intermittent intravenous clodronate in the prevention of bone loss related to chemotherapy-induced ovarian failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15769994" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Pamidronate in the prevention of chemotherapy-induced bone loss in premenopausal women with breast cancer: a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11720830" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Long-term impact of chemotherapy-induced ovarian failure on bone mineral density (BMD) in premenopausal breast cancer patients. The effect of adjuvant clodronate treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21324674" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Zoledronic acid preserves bone mineral density in premenopausal women who develop ovarian failure due to adjuvant chemotherapy: final results from CALGB trial 79809.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18718815" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16014886" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Clinical practice. Screening for osteoporosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16093468" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Clinical practice. Postmenopausal osteoporosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15767532" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Fracture risk among breast cancer survivors: results from the Women's Health Initiative Observational Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Bone Mineral Density (BMD) Changes at 1 Year in Postmenopausal Women Who Are Not Receiving Adjuvant Endocrine Therapy for Breast Cancer (BCA)</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1542321" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23997241" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : NCCN Task Force Report: Bone Health In Cancer Care.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28413771" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Management of Aromatase Inhibitor-Associated Bone Loss (AIBL) in postmenopausal women with hormone sensitive breast cancer: Joint position statement of the IOF, CABS, ECTS, IEG, ESCEO IMS, and SIOG.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33103722" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Fracture risk and management of discontinuation of denosumab therapy: a systematic review and position statement by ECTS.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36656338" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Management of bone loss due to endocrine therapy during cancer treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31752747" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Detection of disseminated tumor cells in bone marrow predict late recurrences in operable breast cancer patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29942922" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Cancer Treatment-Induced Bone Loss in Women With Breast Cancer and Men With Prostate Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29942922" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Cancer Treatment-Induced Bone Loss in Women With Breast Cancer and Men With Prostate Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29942922" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Cancer Treatment-Induced Bone Loss in Women With Breast Cancer and Men With Prostate Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26211824" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29082518" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Bisphosphonates and other bone agents for breast cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37170778" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : The Clinical Benefits of Antiresorptive Agents in Patients with Primary Breast Cancer Receiving Adjuvant Endocrine Therapy: A Systematic Review with Pairwise and Network Meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20202461" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Does adjuvant bisphosphonate in early breast cancer modify the natural course of the disease? A meta-analysis of randomized controlled trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23404816" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Adjuvant therapy with zoledronic acid in patients with breast cancer: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35442755" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Daily Oral Ibandronate With Adjuvant Endocrine Therapy in Postmenopausal Women With Estrogen Receptor-Positive Breast Cancer (BOOG 2006-04): Randomized Phase III TEAM-IIB Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35041467" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Use of Adjuvant Bisphosphonates and Other Bone-Modifying Agents in Breast Cancer: ASCO-OH (CCO) Guideline Update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34165515" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Adjuvant Zoledronate Therapy for Women With Breast Cancer-Effective Treatment or Fool's Gold?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26579489" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Are adjuvant bisphosphonates now standard of care of women with early stage breast cancer? A debate from the Canadian Bone and the Oncologist New Updates meeting.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33755864" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Adjuvant bisphosphonate use in patients with early stage breast cancer: a physician survey.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33680749" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Adjuvant bisphosphonate use in patients with early stage breast cancer: Patient perspectives on treatment acceptability and potential de-escalation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28464216" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Osteoclast inhibition in postmenopausal breast cancer: Is the evidence too strong to ignore?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28464216" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Osteoclast inhibition in postmenopausal breast cancer: Is the evidence too strong to ignore?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28618241" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Use of Adjuvant Bisphosphonates and Other Bone-Modifying Agents in Breast Cancer: A Cancer Care Ontario and American Society of Clinical Oncology Clinical Practice Guideline.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30795951" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Adjuvant denosumab in postmenopausal patients with hormone receptor-positive breast cancer (ABCSG-18): disease-free survival results from a randomised, double-blind, placebo-controlled, phase 3 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31693129" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Phase III Randomized Trial of Bisphosphonates as Adjuvant Therapy in Breast Cancer: S0307.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23980081" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : German adjuvant intergroup node-positive study: a phase III trial to compare oral ibandronate versus observation in patients with high-risk early breast cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26681681" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Adjuvant bisphosphonates in early breast cancer: consensus guidance for clinical practice from a European Panel.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26681681" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Adjuvant bisphosphonates in early breast cancer: consensus guidance for clinical practice from a European Panel.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34165508" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Prognosis of Patients With Early Breast Cancer Receiving 5 Years vs 2 Years of Adjuvant Bisphosphonate Treatment: A Phase 3 Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36592505" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Does the number of 6-monthly adjuvant zoledronate infusions received affect treatment efficacy for early breast cancer? A sub-study of ABCSG-12.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Adjuvant denosumab in early breast cancer: First results from the international multicenter randomized phase III placebo controlled D-CARE study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31806543" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Adjuvant denosumab in early breast cancer (D-CARE): an international, multicentre, randomised, controlled, phase 3 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Long-Term Outcomes of Adjuvant Denosumab in Breast Cancer</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25650170" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Inflammatory eye reactions with bisphosphonates and other osteoporosis medications: what are the risks?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29105841" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Vertebral Fractures After Discontinuation of Denosumab: A Post Hoc Analysis of the Randomized Placebo-Controlled FREEDOM Trial and Its Extension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19521766" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Osteonecrosis of the jaw and use of bisphosphonates in adjuvant breast cancer treatment: a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23796998" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Osteonecrosis of the jaw and oral health-related quality of life after adjuvant zoledronic acid: an adjuvant zoledronic acid to reduce recurrence trial subprotocol (BIG01/04).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31329513" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Medication-Related Osteonecrosis of the Jaw: MASCC/ISOO/ASCO Clinical Practice Guideline.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26209043" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Adjuvant Endocrine Therapy and Bone Health in Breast Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27641143" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Romosozumab Treatment in Postmenopausal Women with Osteoporosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27313945" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Sclerostin Antibody Therapy for the Treatment of Osteoporosis: Clinical Prospects and Challenges.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12090977" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
